Johnson & johnsonJNJ.US Overview
JNJ Overall Performance
JNJ AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
JNJ Current Performance
0.98%
Johnson & johnson
-0.47%
Avg of Sector
-0.64%
S&P500
JNJ Key Information
JNJ Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
JNJ Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
JNJ Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Price of JNJ
JNJ FAQ
When is JNJ's latest earnings report released?
The most recent financial report for Johnson & johnson (JNJ) covers the period of 2025Q2 and was published on 2025/06/29. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JNJ's short-term business performance and financial health. For the latest updates on JNJ's earnings releases, visit this page regularly.
Where does JNJ fall in the P/E River chart?
According to historical valuation range analysis, Johnson & johnson (JNJ)'s current price-to-earnings (P/E) ratio is 18.02, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of JNJ?
According to the latest financial report, Johnson & johnson (JNJ) reported an Operating Profit of 6.65B with an Operating Margin of 27.99% this period, representing a growth of 5.9% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is JNJ's revenue growth?
In the latest financial report, Johnson & johnson (JNJ) announced revenue of 23.74B, with a Year-Over-Year growth rate of 5.77%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does JNJ have?
As of the end of the reporting period, Johnson & johnson (JNJ) had total debt of 50.76B, with a debt ratio of 0.26. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does JNJ have?
At the end of the period, Johnson & johnson (JNJ) held Total Cash and Cash Equivalents of 18.58B, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does JNJ go with three margins increasing?
In the latest report, Johnson & johnson (JNJ) achieved the “three margins increasing” benchmark, with a gross margin of 67.9%%, operating margin of 27.99%%, and net margin of 23.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess JNJ's profit trajectory and future growth potential.
Is JNJ's EPS continuing to grow?
According to the past four quarterly reports, Johnson & johnson (JNJ)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of JNJ?
Johnson & johnson (JNJ)'s Free Cash Flow (FCF) for the period is 2.84B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 39.12% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of JNJ?
The latest valuation data shows Johnson & johnson (JNJ) has a Price-To-Earnings (PE) ratio of 18.02 and a Price/Earnings-To-Growth (PEG) ratio of -0.33. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.